Hormones & Intimacy
Where Did My Sex Drive Go? What Women After Menopause Should Know About PT-141
What the research on the FDA-approved desire medication found, and who it's approved for.
Let's talk about the thing nobody talks about at brunch.
You love your partner. You still think they're attractive. But somewhere around menopause, the wanting just... stopped. Not because anything is wrong between you. It's more like someone quietly turned off a switch, and you have no idea where it is.
If that sounds familiar, you're in very good company. In PRESIDE, the largest study of women's sexual health ever done in the U.S. (more than 31,000 women), low desire was the most common sexual problem women reported, and it was most likely to cause real distress in midlife. Among women aged 45 to 65, about 1 in 8 had low desire that bothered them enough to count as a medical condition.
And it matters. Low desire isn't just about sex. Women who live with it often describe feeling frustrated, guilty, sad, and disconnected from their partner, and from themselves. In one large study, low desire was linked to lower relationship satisfaction, not just a less active sex life.
The good news is that there are more options now than ever, and one of the most interesting is a peptide called PT-141. Let's dig into what it is, how it works on the brain, and what women are saying about it.
This article is for education only. It isn't medical advice, and we're not selling anything here.
Why does desire fade after menopause?
Desire isn't one thing. It's your hormones, your brain, your body, and your life all working together. Menopause shakes up every one of those at the same time.
Your hormones drop. Estrogen and testosterone both play a part in desire. As they decline, many women notice they just don't think about sex the way they used to.
Your brain's "go" signals get quieter. Researchers describe desire as a balance between excitement signals (like dopamine) and brakes (like stress and worry). When the excitement side weakens or the brakes get stronger, desire fades, even when you care deeply about your partner.
Your body changes. Lower estrogen can cause vaginal dryness and thinning tissue, which can make intimacy uncomfortable or even painful. When something hurts, your brain learns to avoid it.
Everything else piles on. Poor sleep, hot flashes, weight changes, feeling less confident in your body, and caring for kids or aging parents all leave less room for desire.
That's why there isn't one magic fix. But it's also why a treatment that works on the brain's desire signals has gotten so much attention.
What is PT-141, and how does it work?
PT-141 is the original research name for bremelanotide, a small peptide made of just seven amino acids. It's a man-made version of a hormone your body already makes, called alpha-MSH (alpha-melanocyte-stimulating hormone).
Here's what makes it different: PT-141 works on your brain, not your blood vessels. Viagra works by increasing blood flow, which helps with the physical side of arousal, but it doesn't make you want to be intimate. PT-141 goes after the wanting itself.
This is how researchers think it works:
-
It switches on "desire receptors" in the brain. PT-141 activates melanocortin receptors, especially one called MC4R. These receptors are packed into an area of the hypothalamus called the medial preoptic area, which plays a key role in sexual desire.
-
That triggers a release of dopamine. Dopamine is the brain's "I want that" chemical, the same one behind motivation and anticipation. In animal studies, PT-141 increased dopamine release in this desire center.
-
Desire turns back on. More dopamine in that area means more excitement signals, which helps shift the balance back toward wanting intimacy.
In female animal studies, PT-141 specifically increased the behaviors that show sexual interest, which is part of why researchers believed it could help women with low desire.
One honest note: even the FDA has said the exact way it improves desire in people isn't fully understood yet. The brain pathway above is the leading explanation.
Studied for decades (and discovered by accident)
PT-141 has one of the best origin stories in medicine.
-
1960s: Scientists noticed that giving the hormone alpha-MSH to rats caused sexual arousal. Labs kept studying this for years.
-
1980s: Researchers at the University of Arizona were trying to create a sunless tanning shot that could help protect people from skin cancer. They made a peptide called Melanotan II.
-
1990s: During early human testing, the men in the studies reported an unexpected side effect: sexual arousal. Researchers realized they'd found something much bigger than a tanning shot.
-
2000s: A company called Palatin Technologies refined the molecule to focus on desire and leave the tanning effects behind. That new peptide was PT-141. Early studies tested it as a nasal spray in both men and women.
-
2015 to 2016: Two large clinical trials called RECONNECT tested PT-141 as an injection in 1,267 women with low desire.
-
2019: The FDA approved it under the brand name Vyleesi. It became only the second FDA-approved medication ever for low desire in women.
What the big trials found
In the RECONNECT trials, women using PT-141 had significantly more desire and less distress about their low desire than women on placebo. In a 52-week follow-up, those improvements held up over time, and no new safety concerns showed up.
To be fair, the improvement wasn't huge for everyone. According to the FDA, about 25% of women in the trials said their desire went up in a meaningful way. That means it can work really well for some women and not much for others.
What about women after menopause?
Here's the catch: the big trials only included premenopausal women, so Vyleesi is officially approved only for them.
But PT-141 has been studied in postmenopausal women. In an earlier pilot study of postmenopausal women with arousal problems, using the nasal spray version, 73% of women on PT-141 reported more arousal compared with 23% on placebo, and 46% reported more desire compared with 19%. That study was small, so it's an early signal rather than proof.
Experts have also pointed out that because PT-141 works in the brain rather than through estrogen, there's good reason to think it may help postmenopausal women too. That's why some doctors prescribe it to women after menopause "off-label," meaning for a use the FDA hasn't specifically approved.
What women are saying
Numbers only tell part of the story, so we looked at what real women have shared publicly about their experiences.
On Drugs.com, women rate bremelanotide an average of 7.8 out of 10, and about two-thirds of reviewers said they had a positive experience. A few themes come up again and again:
-
"I want to want it again." Many women describe missing the desire they used to have, even when they still loved and felt attracted to their partner. One reviewer said she simply wanted to feel the way she and her husband did in their 20s, before kids, money, and work got in the way, and that it worked for her.
-
It brought back a spark that felt gone for good. One woman nearing her "golden years" wrote that she'd spent four years not wanting to be touched by her husband, and that PT-141 helped her get that desire back.
-
It feels like it starts in the brain. A 45-year-old woman on WebMD described it as firing up the part of her brain that says "Desire!" and said she felt alive and sexy again.
-
The nausea. This is the most common complaint. However, many women say it passes in minutes.
What else is good to know
It's used "as needed"
Unlike Addyi, the other FDA-approved option, which is a pill you take every day, PT-141 is used only when you want it. In the trials, women gave themselves a small shot under the skin about 45 minutes before intimacy. It can also take a few tries before you notice a difference.
Side effects
In the big trials, the most common side effects were:
-
Nausea: about 40% of women, compared with about 1% on placebo. It's usually strongest the first time and tends to ease with later doses.
-
Flushing: about 20%
-
Headache: about 11%
Who should skip it
PT-141 isn't a good fit if you have uncontrolled high blood pressure or heart disease. It also shouldn't be used with naltrexone, which it can make less effective. Your doctor will want to know all the medications you take.
Don't skip the other pieces
PT-141 works on desire, but it won't fix everything. If dryness or pain is part of the picture, ask your doctor about vaginal estrogen or moisturizers. Hormone therapy, better sleep, and sometimes a sex therapist can all help too. Many women find the biggest change comes from combining a few of these.
The bottom line
Losing your desire after menopause is incredibly common, and it's not a sign that something is wrong with you or your relationship. Hormones, brain chemistry, physical changes, and everyday stress all play a part.
PT-141 is one of the most interesting options out there because it works where desire actually starts: in the brain. It came out of decades of research, it's FDA-approved for premenopausal women, and early studies plus women's own stories suggest it may help some women after menopause too. It isn't for everyone, and the nausea can be a real drawback. But if you miss wanting to be close to your partner, it's worth asking your doctor about.
You deserve to feel desire again, and you don't have to just accept that it's gone.
Keep reading
- When Did I Become a Stranger in My Own Life? Menopause, Peptides, and Feeling Like You Again
- The 3am Wake-Up Call: Why It Happens After Menopause (and How to Fall Back Asleep)
Sources
-
PRESIDE survey of 31,581 U.S. women (Obstetrics & Gynecology, 2008), via Medical News Today
-
HSDD prevalence by age and its impact on women, Journal of Women's Health
-
HSDD and relationship satisfaction (WISHeS study), Menopause, 2006
-
The neurobiology of bremelanotide, CNS Spectrums, 2022
-
Bremelanotide in female animal studies, Journal of Sexual Medicine, 2007
-
RECONNECT phase 3 trials, Obstetrics & Gynecology, 2019
-
RECONNECT 52-week extension, Obstetrics & Gynecology, 2019
-
Pilot study in postmenopausal women, via The Pharma Letter and ClinicalTrials.gov
-
Expert commentary on postmenopausal use, OBG Management, 2019